Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
Phase 2
- Conditions
- Precancerous Condition
- Registration Number
- NCT00002454
- Brief Summary
RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
- Detailed Description
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
New Jersey Medical School
🇺🇸Newark, New Jersey, United States
New Jersey Medical School🇺🇸Newark, New Jersey, United States